We develop antibody-based therapies targeting IL1RAP

See our pipeline

Our goal is to treat cancer as well as inflammatory and autoimmune diseases

See our clinical program

Strong results provide support for our development programs

See our company presentation

2023-11-10 Interview with DiTV

CEO Göran Forsberg comments on the quarterly report

Watch the interview here

2023-10-03 Redeye Autoimmune & Inflammatory Disease Event

David Liberg, CSO Cantargia, presents at Redeye Autoimmune & Inflammatory Disease Event

Watch the interview here

2023-10-02 Interview with Redeye

Redeye interviews CEO Göran Forsberg about new results for nadunolimab monotherapy and IL1RAP as a biomarker presented at AACR

Watch the interview in Swedish here

Current corporate presentation